ATE394110T1 - Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems - Google Patents

Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems

Info

Publication number
ATE394110T1
ATE394110T1 AT99908377T AT99908377T ATE394110T1 AT E394110 T1 ATE394110 T1 AT E394110T1 AT 99908377 T AT99908377 T AT 99908377T AT 99908377 T AT99908377 T AT 99908377T AT E394110 T1 ATE394110 T1 AT E394110T1
Authority
AT
Austria
Prior art keywords
stromal cells
nervous system
central nervous
isolated
treatment
Prior art date
Application number
AT99908377T
Other languages
German (de)
English (en)
Inventor
Darwin Prockop
David Stokes
S Azizi
Donald Phinney
Original Assignee
Univ Mcp Hahnemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcp Hahnemann filed Critical Univ Mcp Hahnemann
Application granted granted Critical
Publication of ATE394110T1 publication Critical patent/ATE394110T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1311—Osteocytes, osteoblasts, odontoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
AT99908377T 1998-02-24 1999-02-24 Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems ATE394110T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/028,395 US6653134B2 (en) 1995-03-28 1998-02-24 Isolated stromal cells for use in the treatment of diseases of the central nervous system

Publications (1)

Publication Number Publication Date
ATE394110T1 true ATE394110T1 (de) 2008-05-15

Family

ID=21843237

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99908377T ATE394110T1 (de) 1998-02-24 1999-02-24 Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems

Country Status (10)

Country Link
US (3) US6653134B2 (enExample)
EP (2) EP1059929B1 (enExample)
JP (2) JP4748855B2 (enExample)
AT (1) ATE394110T1 (enExample)
AU (1) AU2782499A (enExample)
CA (1) CA2321883A1 (enExample)
DE (1) DE69938653D1 (enExample)
ES (1) ES2307332T3 (enExample)
PT (1) PT1059929E (enExample)
WO (1) WO1999043286A2 (enExample)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653134B2 (en) * 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US7022321B2 (en) 1997-04-10 2006-04-04 Eglitis Martin A Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system
WO1999056759A1 (en) * 1998-05-07 1999-11-11 University Of South Florida Bone marrow cells as a source of neurons for brain and spinal cord repair
US7001746B1 (en) 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
US20030082152A1 (en) 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
DK1183035T3 (en) * 1999-05-14 2015-03-09 Ford Henry Health System BONE MARROW TRANSPLANT TREATMENT stroke
US8017112B2 (en) 1999-05-14 2011-09-13 Henry Ford Health System Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
DK1226233T3 (da) * 1999-08-05 2011-10-03 Abt Holding Co Multipotente voksne stamceller og fremgangsmåder til isolering heraf
US8609412B2 (en) * 1999-08-05 2013-12-17 Regents Of The University Of Minnesota Mapc generation of lung tissue
US7015037B1 (en) * 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US7927587B2 (en) * 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
ATE370225T1 (de) 2000-02-11 2007-09-15 Philadelphia Health & Educatio Differenzierung von knochenmarkzellen in neuronale zellen und deren verwendungen
EP1261694B1 (en) 2000-02-26 2008-01-16 Artecel, Inc. Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
US7582292B2 (en) * 2000-02-26 2009-09-01 Artecel, Inc. Adipose tissue derived stromal cells for the treatment of neurological disorders
IL151650A0 (en) * 2000-03-09 2003-04-10 Saneron Ccel Therapeutics Inc Human cord blood as a source of neural tissue for repair of the brain and spinal cord
ATE330001T1 (de) * 2000-04-12 2006-07-15 Philadelphia Children Hospital Therapeutische verwendung mesenchymaler stromazellen
US6673606B1 (en) 2000-04-12 2004-01-06 The Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells
EP1302534A4 (en) * 2000-06-26 2004-06-16 Renomedix Inst Inc CELL FRACTION WITH CELLS WHICH ARE ABLE TO DIFFERENTIATE IN NERVOUS CELLS
WO2002034889A2 (en) * 2000-10-24 2002-05-02 Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells
CA2438501C (en) * 2001-02-14 2014-09-16 Leo T. Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US20030003090A1 (en) 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
DE10144326B4 (de) * 2001-09-10 2005-09-22 Siemens Ag Verfahren und System zur Überwachung eines Reifenluftdrucks
US9969980B2 (en) * 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US8105580B2 (en) 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
AU2003209259A1 (en) 2002-01-14 2003-07-30 The Board Of Trustees Of The University Of Illinois Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
US20060104962A1 (en) * 2002-07-25 2006-05-18 The Scripps Research Institute Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
US9969977B2 (en) * 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
EP1795595A1 (en) 2002-10-22 2007-06-13 Eisai R&D Management Co., Ltd. Gene specifically expressed in postmitotic dopaminergic neuron precursor cells
WO2004050859A2 (en) 2002-11-27 2004-06-17 Regents Of The University Of Minnesota Homologous recombination in multipotent adult progenitor cells
US7485460B2 (en) 2003-05-21 2009-02-03 Tulane University Health Sciences Center Enhanced growth of adult stem cells with Dkk-1
WO2005003320A2 (en) * 2003-07-02 2005-01-13 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
US20050002904A1 (en) * 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
JP2007513188A (ja) 2003-12-04 2007-05-24 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ リソソーム蓄積症の処置のための組成物および方法
EP2298861B1 (en) 2004-03-22 2017-09-13 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
JP2007532112A (ja) 2004-04-12 2007-11-15 サンバイオ，インコーポレイティド ニューロン始原細胞特性を示す細胞
US20080199437A1 (en) 2004-07-22 2008-08-21 Eisai Co., Ltd. Lrp4/Corin Dopaminergic Neuron Progenitor Cell Markers
WO2006046583A1 (ja) * 2004-10-26 2006-05-04 Santen Pharmaceutical Co., Ltd. 視細胞またはその機能を再生させるための材料
WO2006056998A2 (en) * 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Methods of cell therapy, neurogenesis and oligodendrogenesis
EP2428563A1 (en) * 2005-02-10 2012-03-14 Regents Of The University Of Minnesota Vascular/lymphatic endothelial cells
US20080311084A1 (en) * 2005-05-05 2008-12-18 Verfaillie Catherine M Mapc Engraftment in the Hematopoietic System
AU2005331559B2 (en) * 2005-05-05 2012-04-19 Regents Of The University Of Minnesota Use of NK cell inhibition to facilitate persistence of engrafted MHC-I negative cells
JP2006345726A (ja) * 2005-06-14 2006-12-28 Hamamatsu Univ School Of Medicine 脳腫瘍治療用発現ベクター
ES2524996T3 (es) * 2005-06-16 2014-12-16 Ramot At Tel Aviv University Ltd. Células aisladas y poblaciones que comprenden a las mismas para el tratamiento de enfermedades del SNC
US20080194024A1 (en) * 2005-07-29 2008-08-14 Mays Robert W Culture of Non-Embryonic Cells at High Cell Density
CN101292031A (zh) 2005-08-18 2008-10-22 卫材R&D管理有限公司 多巴胺能神经元增殖祖细胞的标记物Nato3
KR101022401B1 (ko) * 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
SG169324A1 (en) * 2005-10-14 2011-03-30 Univ Minnesota Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype
US20080286249A1 (en) * 2006-01-12 2008-11-20 Varney Timothy R Use of mesenchymal stem cells for treating genetic diseases and disorders
GB0600972D0 (en) * 2006-01-18 2006-03-01 Univ Leeds Enrichment of cells
WO2007100892A2 (en) * 2006-02-28 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Trojan horse immunotherapy
CA2649250A1 (en) 2006-04-11 2007-10-25 Eisai R & D Management Co., Ltd. Dopaminergic neuron progenitor cell marker 187a5
US20120027729A1 (en) * 2006-04-28 2012-02-02 Tulane University Health Sciences Center Methods for treating diabetes
EA201070022A1 (ru) * 2007-06-15 2010-06-30 Гарнет Байотерапьютикс Инк. Лечение заболеваний и нарушений с использованием самообновляющихся образующих колонии клеток, культивированных и размноженных in vitro
CA2712496C (en) 2008-01-18 2021-01-12 Wei-Shou Hu Stem cell aggregates and methods for making and using
US9173862B2 (en) 2008-04-18 2015-11-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona Methods and compositions for treating and identifying compounds to treat age-related macular degeneration
DK2285951T3 (en) 2008-05-28 2018-10-22 Univ Ramot TREATMENT OF CNS DISEASES OF CNS DISEASES
WO2010021993A1 (en) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
US9057051B2 (en) 2008-10-31 2015-06-16 Katholieke Universiteit Leuven Optimized methods for differentiation of cells into cells with hepatocyte progenitor phenotypes, cells produced by the methods, and methods of using the cells
AU2010276201B2 (en) * 2009-07-21 2013-10-17 Healios K.K. Use of stem cells to reduce leukocyte extravasation
SG10201404281YA (en) * 2009-07-21 2014-09-26 Abt Holding Co Use of stem cells to reduce leukocyte extravasation
WO2011106476A1 (en) * 2010-02-25 2011-09-01 Abt Holding Company Modulation of microglia activation
US20110206647A1 (en) * 2010-02-25 2011-08-25 Abt Holding Company Modulation of Angiogenesis
SG10201913920PA (en) 2010-05-12 2020-03-30 Abt Holding Co Modulation of splenocytes in cell therapy
WO2011158125A2 (en) 2010-06-17 2011-12-22 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
SG10201914007YA (en) 2010-08-24 2020-03-30 Univ Minnesota Non-static suspension culture of cell aggregates
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
WO2012156968A2 (en) 2011-05-19 2012-11-22 Ariel - University Research And Development Company, Ltd. Use of mesenchymal stem cells for the improvement of affective and cognitive function
WO2013015457A1 (en) 2011-07-27 2013-01-31 Kyoto University Novel markers for dopaminergic neuron progenitor cells
CN107260760B (zh) 2013-02-06 2021-08-31 Nc医学研究公司 用于治疗神经变性的细胞疗法
AU2014250761B2 (en) 2013-04-12 2019-02-28 Robert J. Deans Improving organs for transplantation
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
CN104161771A (zh) * 2014-04-09 2014-11-26 大连医科大学 骨髓间充质干细胞来源的神经细胞作为治疗正己烷致周围性神经病的药物的应用
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
HK1256413A1 (zh) 2016-01-21 2019-09-20 Abt Holding Company 用於伤口癒合的干细胞
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11464804B1 (en) 2017-11-15 2022-10-11 Enrico Stazzone Intrathecal multifactorial infusion of heterogeneous autologous cell therapy
CN112004923A (zh) 2017-11-22 2020-11-27 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
JPS6030654B2 (ja) * 1980-12-31 1985-07-17 株式会社林原生物化学研究所 ヒトコロニ−刺激因子の製造方法
US4806355A (en) 1983-06-06 1989-02-21 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4608199A (en) * 1984-03-20 1986-08-26 Arnold Caplan Bone protein purification process
US4609551A (en) * 1984-03-20 1986-09-02 Arnold Caplan Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites
US4620327A (en) * 1984-07-05 1986-11-04 Caplan Arnold I Process of adapting soluble bone protein for use in stimulating osteoinduction
US4666828A (en) * 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) * 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4678470A (en) * 1985-05-29 1987-07-07 American Hospital Supply Corporation Bone-grafting material
US4997443A (en) 1985-08-26 1991-03-05 Hana Biologics, Inc. Transplantable artificial tissue and process
US4902295A (en) 1985-08-26 1990-02-20 Hana Biologics, Inc. Transplantable artificial tissue
US4942129A (en) 1987-07-28 1990-07-17 Queen's University At Kingston Multiple membrane microencapsulation
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4904259A (en) 1988-04-29 1990-02-27 Samuel Itay Compositions and methods for repair of cartilage and bone
US5272057A (en) * 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
ES2060942T3 (es) 1989-02-02 1994-12-01 Joel S Greenberger Terapia genetica utilizando celulas estromicas.
US5192659A (en) * 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US5344454A (en) 1991-07-24 1994-09-06 Baxter International Inc. Closed porous chambers for implanting tissue in a host
US5314471A (en) 1991-07-24 1994-05-24 Baxter International Inc. Tissue inplant systems and methods for sustaining viable high cell densities within a host
US5226914A (en) * 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5197985A (en) * 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5334640A (en) 1992-04-08 1994-08-02 Clover Consolidated, Ltd. Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods
AU690548B2 (en) * 1993-04-13 1998-04-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of neuro-derived fetal cell lines for transplantation therapy
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5571083A (en) * 1994-02-18 1996-11-05 Lemelson; Jerome H. Method and system for cell transplantation
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US6126936A (en) * 1995-03-10 2000-10-03 Biohybrid Technologies Llc Microcapsules and composite microreactors for immunoisolation of cells
EP1304113B1 (en) * 1995-03-28 2007-07-25 Thomas Jefferson University Isolated stromal cells and methods of using the same
US6653134B2 (en) * 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US5716616A (en) * 1995-03-28 1998-02-10 Thomas Jefferson University Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US5842477A (en) * 1996-02-21 1998-12-01 Advanced Tissue Sciences, Inc. Method for repairing cartilage
US6342479B1 (en) * 1997-04-08 2002-01-29 Societe De Counseils De Recherches Et D'applications Scientifiques, Sas Prolonging survival of transplanted pancreatic cells
WO1999056759A1 (en) * 1998-05-07 1999-11-11 University Of South Florida Bone marrow cells as a source of neurons for brain and spinal cord repair
US8017112B2 (en) * 1999-05-14 2011-09-13 Henry Ford Health System Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
US20050169896A1 (en) * 1999-05-14 2005-08-04 Henry Ford Health System Bone marrow transplantation for treatment of stroke
DK1183035T3 (en) * 1999-05-14 2015-03-09 Ford Henry Health System BONE MARROW TRANSPLANT TREATMENT stroke
WO2007106200A2 (en) * 2006-01-10 2007-09-20 Theradigm, Inc. Expansion and differentiation of neural stem cells under low oxygen conditions

Also Published As

Publication number Publication date
ES2307332T3 (es) 2008-11-16
JP2002504503A (ja) 2002-02-12
EP1059929A2 (en) 2000-12-20
US6653134B2 (en) 2003-11-25
AU2782499A (en) 1999-09-15
DE69938653D1 (de) 2008-06-19
WO1999043286A2 (en) 1999-09-02
JP4748855B2 (ja) 2011-08-17
US20090214492A1 (en) 2009-08-27
US20030039639A1 (en) 2003-02-27
EP1059929A4 (en) 2002-07-17
EP1815862A1 (en) 2007-08-08
US20040091464A1 (en) 2004-05-13
EP1059929B1 (en) 2008-05-07
CA2321883A1 (en) 1999-09-02
WO1999043286A3 (en) 1999-12-02
PT1059929E (pt) 2008-10-14
JP2010209074A (ja) 2010-09-24

Similar Documents

Publication Publication Date Title
ATE394110T1 (de) Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems
Riess et al. Embryonic stem cell transplantation after experimental traumatic brain injury dramatically improves neurological outcome, but may cause tumors
Kim et al. Neural stem cell‐based treatment for neurodegenerative diseases
Kim Genetically engineered human neural stem cells for brain repair in neurological diseases
Yoshii et al. Restoration of function after spinal cord transection using a collagen bridge
EP2099901B1 (en) Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells
DE68908971D1 (de) Verwendung von physiologisch wirksamen Substanzen zur Herstellung von Medikamenten für Gehirn- und Nervenerkrankungen.
DE60125335D1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
ATE338813T1 (de) Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen
JP2002518990A5 (enExample)
RU2216336C2 (ru) Трансплантация гемопоэтических клеток
Aliaghaei et al. Neuro-restorative effect of sertoli cell transplants in a rat model of amyloid beta toxicity
Krueger et al. Effects of low-intensity electrical stimulation and adipose derived stem cells transplantation on the time-domain analysis-based electromyographic signals in dogs with SCI
Xue et al. Development of a chemically extracted acellular muscle scaffold seeded with amniotic epithelial cells to promote spinal cord repair
ES2369259T3 (es) Células de schwann derivadas de células estrómicas de médula ósea.
Döbrössy et al. Optimising plasticity: environmental and training associated factors in transplant-mediated brain repair
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
KR100959995B1 (ko) 인간 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는,신경전구세포 또는 신경줄기세포의 신경세포로의 분화 및증식 유도용 조성물
ATE437641T1 (de) Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis
CN115348881A (zh) 磁场暴露系统及其用途
KR101603475B1 (ko) 전기자극을 이용하여 중간엽 줄기세포를 연골세포로 분화시키는 방법
Sumarwotoa et al. Enhancement of Schwann-like cells differentiation from adipose-derived mesenchymal stem cells by administration of platelet-rich plasma: An in vitro study
WO2017131353A1 (ko) 섬유아세포의 연골세포로의 교차분화 유도방법
WO2016153114A1 (ko) 고강도 전자기장과 음파 또는 초음파를 이용한 신경재생시스템
DE69429657D1 (de) Verwendung von modifizierten tall-104 zellen zur behandlung von krebs und viralen krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1059929

Country of ref document: EP